[go: up one dir, main page]

CN1330639C - 晶体药物 - Google Patents

晶体药物 Download PDF

Info

Publication number
CN1330639C
CN1330639C CNB018076882A CN01807688A CN1330639C CN 1330639 C CN1330639 C CN 1330639C CN B018076882 A CNB018076882 A CN B018076882A CN 01807688 A CN01807688 A CN 01807688A CN 1330639 C CN1330639 C CN 1330639C
Authority
CN
China
Prior art keywords
robinavir
solid
solvated
lopinavir
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB018076882A
Other languages
English (en)
Chinese (zh)
Other versions
CN1422259A (zh
Inventor
D·A·迪克曼
S·切姆伯卡
J·J·福尔特
R·F·亨赖
D·勒楚加－巴勒斯特罗斯
Y·牛
W·波特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1330639(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN1422259A publication Critical patent/CN1422259A/zh
Application granted granted Critical
Publication of CN1330639C publication Critical patent/CN1330639C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB018076882A 2000-03-30 2001-03-21 晶体药物 Expired - Lifetime CN1330639C (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/538,257 2000-03-30
US09/793,536 2001-02-27
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical
PCT/US2001/009112 WO2001074787A2 (fr) 2000-03-30 2001-03-21 Produit pharmaceutique cristallise

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2007101123988A Division CN101066952A (zh) 2000-03-30 2001-03-21 晶体药物

Publications (2)

Publication Number Publication Date
CN1422259A CN1422259A (zh) 2003-06-04
CN1330639C true CN1330639C (zh) 2007-08-08

Family

ID=27065762

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018076882A Expired - Lifetime CN1330639C (zh) 2000-03-30 2001-03-21 晶体药物
CNA2007101123988A Pending CN101066952A (zh) 2000-03-30 2001-03-21 晶体药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007101123988A Pending CN101066952A (zh) 2000-03-30 2001-03-21 晶体药物

Country Status (22)

Country Link
EP (1) EP1268442A2 (fr)
JP (1) JP2003529592A (fr)
KR (1) KR100773258B1 (fr)
CN (2) CN1330639C (fr)
AR (2) AR033360A1 (fr)
AU (3) AU2001250920B2 (fr)
BG (1) BG107165A (fr)
BR (1) BR0109433A (fr)
CA (1) CA2403635A1 (fr)
CZ (1) CZ20023529A3 (fr)
HU (1) HUP0302675A3 (fr)
IL (1) IL151551A0 (fr)
MX (1) MXPA02009559A (fr)
MY (1) MY128296A (fr)
NO (1) NO325005B1 (fr)
NZ (1) NZ521183A (fr)
PE (1) PE20011232A1 (fr)
PL (1) PL359727A1 (fr)
SA (2) SA06270303B1 (fr)
SK (1) SK14832002A3 (fr)
TW (1) TWI284640B (fr)
WO (1) WO2001074787A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8445506B2 (en) 2009-02-06 2013-05-21 Hetero Research Foundation Polymorphs of lopinavir
CA2770338A1 (fr) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Procedes de preparation d'inhibiteurs de protease du virus de l'hepatite c
CN112830899A (zh) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 一种洛匹那韦新晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998057648A1 (fr) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Procede d'amelioration de la biodisponibilite des polymorphes cristallins stables d'un compose
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (fr) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Procede d'amelioration de la biodisponibilite des polymorphes cristallins stables d'un compose

Also Published As

Publication number Publication date
AR049560A2 (es) 2006-08-16
BG107165A (bg) 2003-07-31
SA06270303B1 (ar) 2009-08-02
AR033360A1 (es) 2003-12-17
NO325005B1 (no) 2008-01-14
KR20030011807A (ko) 2003-02-11
CA2403635A1 (fr) 2001-10-11
SK14832002A3 (sk) 2003-02-04
KR100773258B1 (ko) 2007-11-05
AU5092001A (en) 2001-10-15
CZ20023529A3 (cs) 2003-02-12
TWI284640B (en) 2007-08-01
MY128296A (en) 2007-01-31
CN1422259A (zh) 2003-06-04
NO20024679L (no) 2002-09-30
AU2001250920B2 (en) 2006-06-29
HUP0302675A3 (en) 2004-03-29
MXPA02009559A (es) 2003-05-21
NO20024679D0 (no) 2002-09-30
IL151551A0 (en) 2003-04-10
EP1268442A2 (fr) 2003-01-02
PL359727A1 (en) 2004-09-06
PE20011232A1 (es) 2001-12-08
SA01220270B1 (ar) 2006-11-14
CN101066952A (zh) 2007-11-07
AU2006222711A1 (en) 2006-10-19
WO2001074787A2 (fr) 2001-10-11
JP2003529592A (ja) 2003-10-07
NZ521183A (en) 2004-03-26
WO2001074787A3 (fr) 2002-02-07
BR0109433A (pt) 2004-08-10
HUP0302675A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
US8796451B2 (en) Crystalline pharmaceutical
US20090247532A1 (en) Crystalline polymorph of sitagliptin phosphate and its preparation
WO2014195966A2 (fr) Forme amorphe de canagliflozine et son procédé de préparation
US20160083345A1 (en) Polymorphic forms of lomitapide and its salts and processes for their preparation
CN1330639C (zh) 晶体药物
US9879011B2 (en) Amorphous form of linagliptin and process for preparation thereof
KR20090082399A (ko) 벤조티오펜 화합물의 결정형 및 그의 제조방법
KR100752549B1 (ko) 카르베딜올의 유사다형태
US12492192B2 (en) Crystalline form of lifitegrast, and pharmaceutical composition comprising the same
US9487546B2 (en) Solid forms of tenofovir
WO2018165979A1 (fr) Forme cristalline du 2-(6-méthyl-pyridin-2-yl)-3-yl-[6-amido-quinoléin-4-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole, son procédé de préparation et composition pharmaceutique associée
AU2001250920A1 (en) Crystalline pharmaceutical
CN120693332A (zh) 一种钾离子竞争性酸阻滞剂的稳定无定形形式及其制备方法
CN102428098A (zh) {[(2s，5r，8s，11s)-5-苄基-11-(3-胍基-丙基)-8-异丙基-7-甲基-3，6，9，12，15-五氧代-1，4，7，10，13-五氮杂-环十五烷-2-基]-乙酸}的新固体物质和获得它们的方法
ZA200206962B (en) Crystalline pharmaceutical.
EP4469459B1 (fr) Procédé de préparation de monohydrate d'hydrochlorure de sitagliptine cristallin
WO2019011316A1 (fr) Forme cristalline d'un inhibiteur de kinase btk et son procédé de préparation
CN121405685A (zh) 一种布瑞哌唑-马来酸-甲醇晶型

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ABBOTT PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: ABBOTT LAB

CP01 Change in the name or title of a patent holder

Address after: Illinois State

Patentee after: ABBOTT LABORATORIES

Address before: Illinois State

Patentee before: ABBOTT LABORATORIES

ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130618

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20130618

Address after: Illinois State

Patentee after: ABBVIE

Address before: Illinois State

Patentee before: ABBOTT LABORATORIES

AV01 Patent right actively abandoned
AV01 Patent right actively abandoned
AV01 Patent right actively abandoned

Granted publication date: 20070808

Effective date of abandoning: 20200403

AV01 Patent right actively abandoned

Granted publication date: 20070808

Effective date of abandoning: 20200403